Analysis of peripheral levels of mGlu3R in humans with mild cognitive impairment: an approach towards novel Alzheimer’s biomarkers.

ALBANY SÁEZ; MARÍA MICAELA CASTRO; EUGENIA OLIVERA; PILAR GARAVENTA; ROMINA PAVON; ALEJANDRO DAVID MORONI; NATALIA ERICA MENITE; GASTÓN VILLAFAÑE; ANA CLARA ROMERO; JULIETA SABA; LILA CARNIGLIA; MERCEDES LASAGA; CARLA CARUSO; MARÍA LAURA PALUMBO; DANIELA ELIZABETH DURAN

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencias; 2023

SAIC, SAB, AAFE y AACyTAL

Subtype 3 metabotropic glutamate receptor (mGlu3R) has a broad range of neuroprotective effects. Previously, we demonstrated that astroglial activation of mGlu3R protects hippocampal neurons from Aβ toxicity through both neurotrophin stimulation and Aβ clearance. Using the PDAPP-J20 Alzheimer’s transgenic model, we showed that mGlu3R levels significantly decrease in hippocampus, predisposing to a state of neurotoxicity. Given this, we aim to determine if mGlu3R can be detected in human serum to be used as a new biomarker for cognitive impairment. Mild cognitive impairment (MCI) is an early stage of memory loss or other cognitive decline, whichmay progress to dementia, and constitutes a strategic time window for accurate diagnosis and therapeutic intervention. Individuals from Junín, Buenos Aires, aged 70.46±7.82 years were classified through various neurocognitive tests into Control and MCI groups (n=5-8).Blood samples were taken after informed consent, serum was isolated and Western blots for mGlu3R and Aβ were performed. Interestingly, mGlu3R could be detected in the serum of both groups. We found a 34.5% decrease in the levels of the dimeric form of the receptor in the MCI group (p